Standard BioTools Inc. (NASDAQ:LAB) Stake Cut by Nuveen Asset Management LLC

Nuveen Asset Management LLC cut its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB) by 2.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 798,482 shares of the company’s stock after selling 24,003 shares during the quarter. Nuveen Asset Management LLC owned 0.21% of Standard BioTools worth $1,397,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of Standard BioTools by 13.2% during the third quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock worth $6,231,000 after purchasing an additional 377,195 shares during the period. Invesco Ltd. lifted its position in Standard BioTools by 7.5% in the 4th quarter. Invesco Ltd. now owns 175,041 shares of the company’s stock worth $306,000 after buying an additional 12,194 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Standard BioTools by 9.3% during the 4th quarter. Northern Trust Corp now owns 2,875,160 shares of the company’s stock valued at $5,032,000 after buying an additional 243,522 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Standard BioTools by 27.9% during the 4th quarter. MetLife Investment Management LLC now owns 183,382 shares of the company’s stock valued at $321,000 after buying an additional 40,057 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Standard BioTools by 34.2% during the 4th quarter. SG Americas Securities LLC now owns 135,927 shares of the company’s stock valued at $238,000 after acquiring an additional 34,670 shares in the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Standard BioTools Price Performance

LAB opened at $1.07 on Wednesday. The company has a market capitalization of $406.41 million, a PE ratio of -1.51 and a beta of 1.80. Standard BioTools Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $2.60. The business has a 50-day moving average of $1.10 and a 200-day moving average of $1.41.

Wall Street Analyst Weigh In

Separately, KeyCorp downgraded shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.